Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 6, June, p. 857–862

doi: 10.17219/acem/68981

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Fibrin sealants in cardiac surgery: The last five years of their development and application

Robert Novotny1,2,A,B,C,D, Jaroslav Hlubocký1,3,E, Petr Mitáš1,3,B,C, Jaroslav Lindner1,3,E,F

1 2nd Surgical Clinic of Cardiovascular Surgery, General Teaching Hospital, Prague, Czech Republic

2 Transplant Surgery Department, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

3 1st Faculty of Medicine, Charles University, Prague, Czech Republic

Abstract

This review article describes the use of fibrin glue or fibrin sealants and their development over the past 5 years, with a focus on cardiac surgery. The roles of various types of sealants that are available in hemostasis control are reviewed briefly, together with the various potential risks and side effects of their use. The results of experimental work reported during the last 5 years, clinical data from the same period and the safety aspects of fibrin-based glues and sealants are summarized, showing many advantages of their clinical application over the use of synthetic glues or sealants that may be stronger in some cases, but less safe. It can be concluded that the widespread use of fibrin sealants is fully justified, as it benefits the patient as well as the surgeon through the improved control of hemostasis without increasing any adverse effects or complications during surgical procedures.

Key words

hemostasis, cardiac surgery, fibrin sealants

References (52)

  1. Spotnitz WD. Hemostats, sealants, and adhesives: A practical guide for the surgeon. Am Surg. 2012;78:1305–1321.
  2. Spotnitz WD. Fibrin sealant: The only approved hemostat, sealant, and adhesive – a laboratory and clinical perspective. ISRN Surg. 2014;203943. doi: 10.1155/2014/203943
  3. Schexneider KI. Fibrin sealants in surgical or traumatic hemorrhage. Curr Opin Hematol. 2004;11:323–326.
  4. Kouba E, Tornehl C, Lavelle J, Wallen E, Pruthi RS. Partial nephrectomy with fibrin glue repair: Measurement of vascular and pelvicalyceal hydrodynamic bond integrity in a live and abbatoir porcine model. J Urol. 2004;172:326–330.
  5. Dalvi AA, Faria MM, Pinto AA. Non-suture closure of wound using cyanoacrylate. J Postgrad Med. 1986;32:97–100. Accessed Junuary 13, 2018.
  6. Duvvi SK, Lo S, Kumar R, Spraggs P. Superglue (cyanoacrylate) in the nose. Otolaryngol Head Neck Surg. 2005;133:803–804.
  7. Ellegala DB, Maartens NF, Laws ER Jr. Use of FloSeal hemostatic sealant in transsphenoidal pituitary surgery: Technical note. Neurosurgery. 2002;51:513–515.
  8. Krause TL, Bittner GD. Rapid morphological fusion of severed myelinated axons by polyethylene glycol. Proc Natl Acad Sci USA. 1990;87:1471–1475.
  9. Stavisky RC, Britt JM, Zuzek A, Truong E, Bittner GD. Melatonin enhances the in vitro and in vivo repair of severed rat sciatic axons. Neurosci Lett. 2005;376:98–101.
  10. Miscusi M, Polli FM, Forcato S, et al. The use of surgical sealants in the repair of dural tears during non-instrumented spinal surgery. Eur Spine J. 2014;23:1761–1766.
  11. Bhamidipati CM, Coselli JS, LeMaire SA. BioGlue in 2011: What is its role in cardiac surgery? J Extra Corpor Technol. 2012;44:6–12.
  12. Smith TE. Mechanism of blood coagulation. In: Devlin TM, ed. Textbook of Biochemistry with Clinical Correlations. 7th ed. Hoboken, NJ: John Wiley & Sons; 2010:1031–1048.
  13. Immuno AG. Tisseel® Product Information, 1998. http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/fractionatedplasmaproducts/ucm073008.pdf. Accessed December 20, 2015.
  14. Gupta N, Chetter I, Hayes P, et al. Randomized trial of a dry-powder, fibrin sealant in vascular procedures. J Vasc Surg. 2015;62:1288–1295.
  15. Verhoef C, Singla N, Moneta G, et al. Fibrocaps for surgical hemostasis: Two randomized, controlled phase II trials. J Surg Res. 2015;194:679–687.
  16. Kawamura M, Sawafuji M, Watanabe M, Horinouchi H, Kobayashi K. Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg. 2002;73:1098–1100.
  17. Hino M, Ishiko O, Honda KI, et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol. 2000;108:194–195.
  18. Wu X, Ren J, Yao G, et al. Biocompatibility, biodegradation, and neovascularization of human single-unit platelet-rich fibrin glue: An in vivo analysis. Chin Med J (Engl). 2014;127:408–411.
  19. Kasahara H, Hayashi I. Polyglycolic acid sheet with fibrin glue potentiates the effect of a fibrin-based haemostat in cardiac surgery. J Cardiothorac Surg. 2014;9:121. doi: 10.1186/1749-8090-9-121
  20. Kin H, Nakajima T, Okabayashi H. Experimental study on effective application of fibrin glue. Gen Thorac Cardiovasc Surg. 2012;60:140–144.
  21. Almeida MJ, Yoshida WB, Hafner L, et al. Biomechanical and histologic analysis in aortic endoprosthesis using fibrin glue. J Vasc Surg. 2011;53:1368–1374.
  22. Oda S, Morita S, Tanoue Y, Eto M, Matsuda T, Tominaga R. Experimental use of an elastomeric surgical sealant for arterial hemostasis and its long-term tissue response. Interact Cardiovasc Thorac Surg. 2010;10:258–261.
  23. Rousou JA. Use of fibrin sealants in cardiovascular surgery: A systematic review. J Card Surg. 2013;28:238–247.
  24. Della Corte A, Baldascino F, La Marca F, et al. Hemostatic modifications of the Bentall procedure: Imbricated proximal suture and fibrin sealant reduce postoperative morbidity and mortality rates. Tex Heart Inst J. 2012;39:206–210.
  25. Garcia-Villarrea OA, Casillas-Covarrubias LE. Fibrin sealant for left ventricular rupture after mitral valve replacement. Asian Cardiovasc Thorac Ann. 2008;16:152–153.
  26. Cardillo G, Carleo F, Carbone L, et al. Adverse effects of fibrin sealants in thoracic surgery. The safety of a new fibrin sealant: Multicenter, randomized, controlled, clinical trial. Eur J Cardiothorac Surg. 2012; 41:657–662.
  27. Vida VL, De Franceschi M, Barzon E, Padalino MA, Scattolin F, Stellin G. The use fibrinogen/thrombin-coated equine collagen patch in children requiring reoperations for congenital heart disease: A single center clinical experience. J Cardiovasc Surg (Torino). 2014;55:401–406.
  28. Vida VL, Padalino MA, Barzon E, Stellin G. Efficacy of fibrinogen/thrombin-coated equine collagen patch in controlling lymphatic leaks. J Card Surg. 2012;27:441–442.
  29. Tashnizi MA, Alamdari DH, Khayami ME, et al. Treatment of non-healing sternum wound after open-heart surgery with allogenic platelet-rich plasma and fibrin glue-preliminary outcomes. Indian J Plast Surg. 2013;46:538–542.
  30. Sakic A, Chevtchik O, Kilo J, et al. Simple adaptations of surgical technique to critically reduce the risk of postoperative sternal complications in patients receiving bilateral internal thoracic arteries. Interact Cardiovasc Thorac Surg. 2013;17:378–382.
  31. Suzuki T, Wada T, Funaki S, et al. Traumatic left ventricular free-wall laceration by a gunshot: Report of a case. Surg Today. 2014;44:1152–1155.
  32. Suzuki S, Masuda M, Imoto K. The use of surgical glue in acute type A aortic dissection. Gen Thorac Cardiovasc Surg. 2014;62:207–213.
  33. Khan H, Chaubey S, Desai J. Early failure of coronary artery bypass grafts: An albumin cross-linked glutaraldehyde (BioGlue) related complication. J Card Surg. 2011;26:264–266.
  34. Rubio Alvarez J, Sierra Quiroga J, Martinez de Alegria A, Delgado Dominguez C. Pulmonary embolism due to biological glue after repair of type A aortic dissection. Interact Cardiovasc Thorac Surg. 2011;12:650–651.
  35. Alameddine A, Alimov VK, Rousou JA, Freeman J. Aorto-pulmonary artery disruption following acute type-A aortic dissection repair with the use of BioGlue®. J Card Surg. 2012;27:371–373.
  36. Modi A, Bull R, Tsang G, Kaarne M. Ostial left coronary stenosis following aortic root reconstruction with BioGlue. Interact Cardiovasc Thorac Surg. 2011;13:243–245.
  37. Pasic M, Unbehaun A, Drews T, Hetzer R. Late wound healing problems after use of BioGlue for apical hemostasis during transapical aortic valve implantation. Interact Cardiovasc Thorac Surg. 2011;13:532–534.
  38. TachoSil. U.S. Food and Drug Administration. https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm207482. Accessed March 31, 2010.
  39. Feng W, Coady M. Epicardial tachosil patch repair of ventricular rupture in a 90-year-old after mitral valve replacement. Ann Thorac Surg. 2016;101(6):2361–2363.
  40. Giordano R, Palma G, Palumbo S, Cioffi S, Russolillo V, Vosa C. Use of biological hemostatic support TachoSil® for reoperation in pediatric cardiac surgery. Minerva Pediatr. 2016;68(3):240–241.
  41. Labrousse L, Barandon L, Choukroun E, Deville C. ‘Double patch and glue’ technique for early repair of posterior post-infarction ventricular septal defect. Interact Cardiovasc Thorac Surg. 2006;5(3):195–196.
  42. BioGlue. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf/p010003b.pdf. Accessed December 14, 2001.
  43. Zehr KJ. Use of bovine albumin-glutaraldehyde glue in cardiovascular surgery. Ann Thorac Surg. 2007;84:1048–1052.
  44. Higashi R, Matsumura Y, Yamaki F. Posterior ventricular septal perforation: Sandwich technique via right ventriculotomy using BioGlue. Gen Thorac Cardiovasc Surg. 2013;61(8):460–462. doi:10.1007/s11748-012-0172-6
  45. Masroor S, Schor J, Carrillo R, Williams DB. Endoventricular pocket repair of type I myocardial rupture after mitral valve replacement: A new technique using pericardial patch, Teflon felt, and BioGlue. Ann Thorac Surg. 2004;77:1439–1441.
  46. Dunst KM, Antretter H, Bonatti J. Control of suture hole bleeding after aortic valve replacement by application of BioGlue during circulatory arrest. Int Heart J. 2005;46:175–179.
  47. Leva C, Bruno PG, Gallorini C, et al. Complete myocardial revascularization and sutureless technique for left ventricular free wall rupture: Clinical and echocardiographic results. Interact Cardiovasc Thorac Surg. 2006;5:408–412.
  48. Durukan AB, Serter FT, Gurbuz HA, Tavlasoglu M, Ucar HI, Yorgancioglu C. Biological glue application in repair of atrioventricular groove rupture: A case report. J Tehran Heart Cent. 2014;9(3):137–139.
  49. Gil-Jaurena JM, Aroca Á, Pérez-Caballero R, Pita A. Free wall rupture after arterial switch operation. Ann Thorac Surg. 2014;98(6):2230–2231. doi:10.1016/j.athoracsur.2014.01.072
  50. CoSeal. U.S. Food and Drug Administration. www.accessdata.fda.gov/cdrh_docs/pdf/p010022b.pdf. Accessed February 25, 2002.
  51. Pace Napoleone C, Valori A, Crupi G, et al. An observational study of CoSeal for the prevention of adhesions in pediatric cardiac surgery. Interact Cardiovasc Thorac Surg. 2009;9(6):978–982. doi:10.1510/icvts.2009.212175
  52. Garcia-Morales LJ, Ramchandani M, Loebe M, Reardon MJ, Bruckner BA, Ramlawi B. Intraoperative surgical sealant application during cardiac defect repair. Tex Heart Inst J. 2014;41(4):440–442. doi:10.14503/THIJ-13-3347
© Wroclaw Medical University